BROADCASTS.com

b'

In this episode of Psychedelics Weekly, Kyle is joined by another new voice from the PT team: one of the main instructors and facilitators from our Vital program, Diego Pinzon.\\xa0

Originally from Colombia, Diego has been living in Australia since 2008 and has been involved in the Australian psychedelic scene, playing roles in the charity sector, research with Psychae Institute, and is one of the researchers in the St. Vincent\\u2019s Melbourne trial, Australia\\u2019s first trial using psilocybin for end-of-life depression and anxiety. Diego gives his insight into the recent TGA re-scheduling of psilocybin and MDMA for treatment-resistant depression and post-traumatic stress disorder, respectively.

They cover the details, unknowns, and concerns: Is there enough time to train enough people? Do they have the infrastructure for this? What are the substances actually going to be? What percentage of people who apply will be granted access? What will it cost? And while psychiatrists will be able to prescribe, how much will the program really focus on therapy?\\xa0

And they discuss Vancouver\\u2019s Filament Health creating the world\\u2019s first ayahuasca pill, which is close to FDA authorization to begin a Phase 1 trial. Of course this news begs some questions as well, mainly: with psychedelic use being such an active experience, how much does something like this change our relationship to ayahuasca? And with a consistent, more predictable experience, does that kill the magic?

www.psychedelicstoday.com

\\xa0